The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
Open accessAbstract
B cells play an important role in the pathogenesis of systemic lupus erythematosus (SLE), so the safety and activity of anti-B cell immunotherapy with the humanized anti-CD22 antibody epratuzumab was evaluated in SLE patients. An open-label, single-center study of 14 patients with moderately active SLE (total British Isles Lupus Assessment Group (BILAG) score 6 to 12) was conducted. Patients received 360 mg/m 2 epratuzumab intravenously every 2 weeks for 4 doses with analgesic/antihistamine premedication (but no steroids) prior to each dose. Evaluations at 6, 10, 18 and 32 weeks (6 months post-treatment) follow-up included safety, SLE activity (BILAG score), blood levels of epratuzumab, B and T cells, immunoglobulins, and human anti-epratuzumab antibody (HAHA) titers. Total BILAG scores decreased by ≥ 50% in all 14 patients at some point during the study (including 77% with a ≥ 50% decrease at 6 weeks), with 92% having decreases of various amounts continuing to at least 18 weeks (where 38% showed a ≥ 50% decrease). Almost all patients (93%) experienced improvements in at least one BILAG B- or C-level disease activity at 6, 10 and 18 weeks. Additionally, 3 patients with multiple BILAG B involvement at baseline had completely resolved all B-level disease activities by 18 weeks. Epratuzumab was well tolerated, with a median infusion time of 32 minutes. Drug serum levels were measurable for at least 4 weeks post-treatment and detectable in most samples at 18 weeks. B cell levels decreased by an average of 35% at 18 weeks and remained depressed at 6 months post-treatment. Changes in routine safety laboratory tests were infrequent and without any consistent pattern, and there was no evidence of immunogenicity or significant changes in T cells, immunoglobulins, or autoantibody levels. In patients with mild to moderate active lupus, 360 mg/m 2 epratuzumab was well tolerated, with evidence of clinical improvement after the first infusion and durable clinical benefit across most body systems. As such, multicenter controlled studies are being conducted in broader patient populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Epidemiology and estimated population burden of selected autoimmune diseases in the United States
Jacobson, D. L., Gange, S. J., Rose, N. R., & Graham, N. M. H. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4412 · Cited by 1,667
Andrews, B. S., Eisenberg, R. A., Theofilopoulos, A. N., Izui, S., Wilson, C. B., McConahey, P. J., Murphy, E. D., Roths, J. B., & Dixon, F. J. (1978) · The Journal of experimental medicine · doi:10.1084/jem.148.5.1198 · Cited by 1,598
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_7 · Cited by 1,564
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Chan, O. T. M., Hannum, L. G., Haberman, A. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1639 · Cited by 698
Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus
Odendahl, M., Jacobi, A., Hansen, A., Feist, E., Hiepe, F., Burmester, G. R., Lipsky, P. E., Radbruch, A., & Dörner, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5970 · Cited by 642
Self-citationAn open study of B lymphocyte depletion in systemic lupus erythematosus
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 576
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068841 · Cited by 567
Emery, A. E. H. (1997) · Neuromuscular Disorders · doi:10.1016/s0960-8966(96)00406-3 · Cited by 443
Cited by
Rahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Rahman, M. U. (2008) · Essentials of Physical Medicine and Rehabilitation · doi:10.1016/b978-1-4160-4007-1.50153-x · Cited by 1,019
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60128-8 · Cited by 752
Murine Models of Systemic Lupus Erythematosus
Perry, D., Sang, A., Yin, Y., Zheng, Y.-Y., & Morel, L. (2011) · BioMed Research International · doi:10.1155/2011/271694 · Cited by 378
Metadata
- Authors
- Dörner, T., Kaufmann, J., Wegener, W. A., Teoh, N., Goldenberg, D. M., & Burmester, G. R.
- Venue
- Arthritis Research & Therapy
- Published
- 2006-04-21
- Volume
- 8
- Issue
- 3
- Pages
- R74-R74
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2140433336
- Cited by
- 306
- References
- 43
- FWCI
- 20.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. https://app.cochat.ai/papers/10.1186/ar1942
- The paper
- Dörner, T., Kaufmann, J., Wegener, W. A., Teoh, N., Goldenberg, D. M., & Burmester, G. R. (2006). Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Research & Therapy. https://doi.org/10.1186/ar1942
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.